Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Purchased by Arizona State Retirement System

Arizona State Retirement System boosted its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 2.6% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 62,020 shares of the biopharmaceutical company’s stock after buying an additional 1,577 shares during the quarter. Arizona State Retirement System’s holdings in Amicus Therapeutics were worth $615,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Sage Capital Advisors llc purchased a new stake in shares of Amicus Therapeutics during the 2nd quarter worth about $103,000. EntryPoint Capital LLC grew its holdings in Amicus Therapeutics by 278.8% in the first quarter. EntryPoint Capital LLC now owns 13,218 shares of the biopharmaceutical company’s stock valued at $156,000 after purchasing an additional 9,729 shares during the period. Old Well Partners LLC purchased a new stake in shares of Amicus Therapeutics in the fourth quarter valued at approximately $180,000. Mesirow Financial Investment Management Inc. acquired a new position in shares of Amicus Therapeutics during the 1st quarter worth approximately $225,000. Finally, SG Americas Securities LLC acquired a new position in shares of Amicus Therapeutics during the 1st quarter worth approximately $291,000.

Amicus Therapeutics Price Performance

FOLD stock opened at $11.30 on Monday. Amicus Therapeutics, Inc. has a 1 year low of $9.02 and a 1 year high of $14.57. The company has a debt-to-equity ratio of 2.93, a current ratio of 2.75 and a quick ratio of 2.26. The firm has a market capitalization of $3.35 billion, a PE ratio of -23.06 and a beta of 0.69. The business has a 50 day simple moving average of $10.97 and a 200-day simple moving average of $10.77.

Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05). Amicus Therapeutics had a negative return on equity of 41.47% and a negative net margin of 26.23%. The company had revenue of $126.67 million during the quarter, compared to analysts’ expectations of $121.21 million. During the same period in the prior year, the business earned ($0.15) EPS. The firm’s quarterly revenue was up 34.0% on a year-over-year basis. Equities research analysts anticipate that Amicus Therapeutics, Inc. will post -0.08 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a report on Friday, August 9th. Wells Fargo & Company started coverage on shares of Amicus Therapeutics in a research report on Thursday, May 30th. They set an “overweight” rating and a $18.00 price target for the company. JPMorgan Chase & Co. lowered their price objective on Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating on the stock in a report on Friday, August 16th. Finally, Jefferies Financial Group initiated coverage on Amicus Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $18.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, Amicus Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $17.25.

Insiders Place Their Bets

In other news, CEO Bradley L. Campbell sold 6,100 shares of the firm’s stock in a transaction that occurred on Friday, July 5th. The shares were sold at an average price of $10.00, for a total transaction of $61,000.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares in the company, valued at approximately $8,866,540. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Bradley L. Campbell sold 6,100 shares of the company’s stock in a transaction on Friday, July 5th. The stock was sold at an average price of $10.00, for a total value of $61,000.00. Following the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $8,866,540. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $11.71, for a total value of $87,825.00. Following the sale, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at $10,382,718.34. The disclosure for this sale can be found here. Insiders have sold 21,100 shares of company stock valued at $226,375 over the last ninety days. Company insiders own 2.20% of the company’s stock.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.